Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection

MT Newswires Live

03/09

Incyte (INCY) said in a Friday filing that the US Food and Drug Administration did not approve the supplemental biologics application for an additional indication of its Zynyz injection for the treatment of adult patients with metastatic non-small cell lung cancer, combined with platinum-based chemotherapy.

The company said a Feb. 27 complete response letter from the FDA cited certain inspection findings related to Catalent Indiana, the third-party fill-finish facility in the application, as the "sole approvability issue."

Catalent Indiana is a part of Novo Nordisk and Incyte said it is working with the facility and the FDA to address the matter. The FDA's letter did not cite any other concern in the application, the company added.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618647578"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618647578\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618647578?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 18:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618647578","market":"sh","top_or_hot":-1,"title":"Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection","media":"MT Newswires Live","content":"<html><body><p> Incyte (INCY) said in a Friday filing that the US Food and Drug Administration did not approve the supplemental biologics application for an additional indication of its Zynyz injection for the treatment of adult patients with metastatic non-small cell lung cancer, combined with platinum-based chemotherapy.</p><p>The company said a Feb. 27 complete response letter from the FDA cited certain inspection findings related to <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> Indiana, the third-party fill-finish facility in the application, as the \"sole approvability issue.\"</p><p>Catalent Indiana is a part of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and Incyte said it is working with the facility and the FDA to address the matter. The FDA's letter did not cite any other concern in the application, the company added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-09 18:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Incyte (INCY) said in a Friday filing that the US Food and Drug Administration did not approve the supplemental biologics application for an additional indication of its Zynyz injection for the treatment of adult patients with metastatic non-small cell lung cancer, combined with platinum-based chemotherapy.</p><p>The company said a Feb. 27 complete response letter from the FDA cited certain inspection findings related to <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> Indiana, the third-party fill-finish facility in the application, as the \"sole approvability issue.\"</p><p>Catalent Indiana is a part of <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and Incyte said it is working with the facility and the FDA to address the matter. The FDA's letter did not cite any other concern in the application, the company added.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOX","symbol_name":"2倍做多NVO ETF-Defiance","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618647578","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618647578","pubTimestamp":1773052186,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Incyte  said in a Friday filing that the US Food and Drug Administration did not approve the supplemental biologics application for an additional indication of its Zynyz injection for the treatment of adult patients with metastatic non-small cell lung cancer, combined with platinum-based chemotherapy.The company said a Feb. 27 complete response letter from the FDA cited certain inspection findings related to Catalent Indiana, the third-party fill-finish facility in the application, as the \"sole approvability issue.\"Catalent Indiana is a part of Novo Nordisk and Incyte said it is working with the facility and the FDA to address the matter. The FDA's letter did not cite any other concern in the application, the company added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVOX":"2倍做多NVO ETF-Defiance","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","NVO":"诺和诺德","BK4550":"红杉资本持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4585":"ETF&股票定投概念","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LABU":"三倍做多标普生物-Direxion","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","INCY":"因塞特医疗","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Incyte表示FDA拒绝Zynyz注射液的补充生物制剂申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5,"NVOX":0.6,"LABU":1.5,"NVOH":0.6,"NVO":0.9},"content_text":"Incyte (INCY) said in a Friday filing that the US Food and Drug Administration did not approve the supplemental biologics application for an additional indication of its Zynyz injection for the treatment of adult patients with metastatic non-small cell lung cancer, combined with platinum-based chemotherapy.The company said a Feb. 27 complete response letter from the FDA cited certain inspection findings related to Catalent Indiana, the third-party fill-finish facility in the application, as the \"sole approvability issue.\"Catalent Indiana is a part of Novo Nordisk and Incyte said it is working with the facility and the FDA to address the matter. The FDA's letter did not cite any other concern in the application, the company added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}